Immunic, Inc. (ticker: IMUX) announced on September 9, 2026, that it will host a Relapsing Multiple Sclerosis (RMS) Research and Development Day webinar. The event is scheduled to take place on Wednesday, September 9, 2026, from 11:00 a.m. to 12:30 p.m. Eastern Time via video conference.
The company stated that it intends to use a presentation during this webinar, which is attached as Exhibit 99.1 to the current report on Form 8-K filed with the SEC. The filing notes that the information provided in Item 7.01 and the attached exhibit shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934.
The company included a cautionary note regarding forward-looking statements. These statements relate to the company's development programs, the potential for its lead candidate vidofludimus calcium, preclinical and clinical data, the feasibility of advancing the candidate to a confirmatory phase 3 clinical trial, and the timing of clinical milestones and regulatory approvals.
The filing also references the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed on February 26, 2026, which contains a detailed list of risk factors.
